Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366311 | 0.91 | LMNA (0.38) | RAB9AHTTNR3C1TSHRLMNA | |
| SCHEMBL12366289 | 0.88 | RAB9A (0.36) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL12366640 | 0.86 | HTR5A (0.41) | — | |
| SCHEMBL12389224 | 0.85 | PYGL (0.41) | RAB9ANPC1NR3C1MAPTMEN1 | |
| SCHEMBL12366279 | 0.84 | MEN1 (0.40) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL12390006 | 0.82 | ABL1 (0.37) | RAB9ASMN1; SMN2NPC1ALDH1A1NR3C1 | |
| SCHEMBL12389879 | 0.81 | MEN1 (0.42) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL12366285 | 0.80 | PARP1 (0.37) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL12366287 | 0.80 | PARP1 (0.37) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL12389145 | 0.79 | MEN1 (0.37) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | RAB9A 430/4885SMN1; SMN2 3728/4885NPC1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.